Buy or sell Synthorx stock pre IPO via an EquityZen fund
EquityZen is a marketplace for shares of proven pre IPO tech companies

Synthorx Stock
Biotechnology
About Synthorx Stock
Synthorx is a biotechnology company using ground-breaking synthetic biology starting with our novel DNA base pair to discover and develop new protein therapeutics. The company uses new building blocks to create proteins that impart specificity not possible with native proteins. The result is treatments with improved efficacy, better safety, and better convenience for patients. Utilizing proprietary engineered organisms we have the ability to manufacture these improved proteins with high fidelity and the required yield for drug discovery and development. This unique platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies.
Investors
Correlation Ventures
Getaround, Casper, Earnest, Personal Capital, BlueVine, Optimizely, Good Eggs, Lytro, mParticle, Crossbar
Funding History
April 2014 | $6.0M |
---|---|
July 2016 | $10.0M |
April 2018 | $63.0M |
Management
Chief Scientific Officer
Marcos Milla
President and CEO
Laura Shawver
Founder and Director
Floyd E. Romesberg
Press
Wall Streets Journal - Dec, 9 2019
Herald Keeper - Jun, 12 2018
Reuters - Apr, 30 2018
- Apr, 30 2018
Endpoints News - Dec, 1 2017
PR Newswire (press release) - Nov, 29 2017
PR Newswire (press release) - Nov, 27 2017
PR Newswire (press release) - Aug, 14 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Synthorx or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase